Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A5962

Richard E. Harris, Amanda M. Termuhlen, Lynette M Smith, James Lynch, Michael M. Henry, Sherrie L. Perkins, Thomas G. Gross, Phyllis Irene Warkentin, Adrianna Vlachos, Lauren Harrison, Mitchell S. Cairo

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P<.0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for transplanted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30% NHL). The 3-year EFS in transplanted patients is 66% (65% HL; 70% NHL). Initial duration of remission of ≥12 versus <12 months was associated with a significant increase in OS (3 years OS 70% versus 34%) (P=.003). BCNU at 300 mg/m2 in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A short duration (<12 months) of initial remission is associated with a poorer prognosis. Last, a high percentage of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Peripheral Blood Stem Cell Transplantation
Lymphoma
Carmustine
Transplants
Disease-Free Survival
Survival
Blood Component Removal
Granulocyte Colony-Stimulating Factor
Etoposide
Hodgkin Disease
Non-Hodgkin's Lymphoma
Cyclophosphamide
Peripheral Blood Stem Cells
Prospective Studies
Pediatrics
Safety
Lung

Keywords

  • Autologous transplant
  • CBV
  • HL
  • Lymphoma
  • NHL
  • PBSCT

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma : Results of Children's Oncology Group Study A5962. / Harris, Richard E.; Termuhlen, Amanda M.; Smith, Lynette M; Lynch, James; Henry, Michael M.; Perkins, Sherrie L.; Gross, Thomas G.; Warkentin, Phyllis Irene; Vlachos, Adrianna; Harrison, Lauren; Cairo, Mitchell S.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 2, 01.02.2011, p. 249-258.

Research output: Contribution to journalArticle

Harris, Richard E. ; Termuhlen, Amanda M. ; Smith, Lynette M ; Lynch, James ; Henry, Michael M. ; Perkins, Sherrie L. ; Gross, Thomas G. ; Warkentin, Phyllis Irene ; Vlachos, Adrianna ; Harrison, Lauren ; Cairo, Mitchell S. / Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma : Results of Children's Oncology Group Study A5962. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 2. pp. 249-258.
@article{2ea72d2129a642ff9b1bdce4e2fb798f,
title = "Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A5962",
abstract = "This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P<.0001). The probability of overall survival (OS) at 3 years for all patients is 51{\%} and for transplanted patients is 64{\%}. The 3-year event-free survival (EFS) is 38{\%} (45{\%} for HL; 30{\%} NHL). The 3-year EFS in transplanted patients is 66{\%} (65{\%} HL; 70{\%} NHL). Initial duration of remission of ≥12 versus <12 months was associated with a significant increase in OS (3 years OS 70{\%} versus 34{\%}) (P=.003). BCNU at 300 mg/m2 in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A short duration (<12 months) of initial remission is associated with a poorer prognosis. Last, a high percentage of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.",
keywords = "Autologous transplant, CBV, HL, Lymphoma, NHL, PBSCT",
author = "Harris, {Richard E.} and Termuhlen, {Amanda M.} and Smith, {Lynette M} and James Lynch and Henry, {Michael M.} and Perkins, {Sherrie L.} and Gross, {Thomas G.} and Warkentin, {Phyllis Irene} and Adrianna Vlachos and Lauren Harrison and Cairo, {Mitchell S.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.bbmt.2010.07.002",
language = "English (US)",
volume = "17",
pages = "249--258",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma

T2 - Results of Children's Oncology Group Study A5962

AU - Harris, Richard E.

AU - Termuhlen, Amanda M.

AU - Smith, Lynette M

AU - Lynch, James

AU - Henry, Michael M.

AU - Perkins, Sherrie L.

AU - Gross, Thomas G.

AU - Warkentin, Phyllis Irene

AU - Vlachos, Adrianna

AU - Harrison, Lauren

AU - Cairo, Mitchell S.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P<.0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for transplanted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30% NHL). The 3-year EFS in transplanted patients is 66% (65% HL; 70% NHL). Initial duration of remission of ≥12 versus <12 months was associated with a significant increase in OS (3 years OS 70% versus 34%) (P=.003). BCNU at 300 mg/m2 in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A short duration (<12 months) of initial remission is associated with a poorer prognosis. Last, a high percentage of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.

AB - This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P<.0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for transplanted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30% NHL). The 3-year EFS in transplanted patients is 66% (65% HL; 70% NHL). Initial duration of remission of ≥12 versus <12 months was associated with a significant increase in OS (3 years OS 70% versus 34%) (P=.003). BCNU at 300 mg/m2 in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A short duration (<12 months) of initial remission is associated with a poorer prognosis. Last, a high percentage of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.

KW - Autologous transplant

KW - CBV

KW - HL

KW - Lymphoma

KW - NHL

KW - PBSCT

UR - http://www.scopus.com/inward/record.url?scp=79151485721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151485721&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.07.002

DO - 10.1016/j.bbmt.2010.07.002

M3 - Article

C2 - 20637881

AN - SCOPUS:79151485721

VL - 17

SP - 249

EP - 258

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -